Key insights
- Lumexa Imaging reported Q1 2026 earnings that met expectations, with 3% revenue growth driven by advanced modalities. However, the stock plunged over 20% in after-hours trading and continued to fall, signaling investor concern over operational expenses and weather disruptions. Despite the stock's sharp decline and oversold RSI, future EPS growth is projected, with profitability expected this year. The significant stock drop, despite meeting earnings, suggests potential negative sentiment spillover or specific company issues impacting broader market confidence in the healthcare equipment sector.
Lumexa Imaging Holdings Corp. reported its Q1 2026 earnings, meeting expectations with an adjusted EPS of $0.18 and revenues of $253 million. Despite seasonal and weather-related disruptions, the company demonstrated a 3% year-over-year revenue growth. However, the stock experienced a sharp decline, dropping 20.77% in after-hours trading to $8.05 from $10.16.
Lumexa Imaging’s Q1 2026 results reflected resilience in the face of adverse conditions, achieving a 3% revenue increase compared to the same period last year. The company showed strong performance in advanced modalities, particularly in PET and MRI, which contributed significantly to overall growth. Despite these gains, the company faced challenges from seasonal and weather-related disruptions that impacted routine scan volumes.
Lumexa Imaging’s adjusted EPS of $0.18 met analyst expectations, with no earnings surprise. The revenue of $253 million slightly exceeded the forecasted $252.54 million, demonstrating stable performance despite external challenges.
Following the earnings report, Lumexa’s stock price fell 20.77% in after-hours trading, dropping to $8.05. The stock has continued its decline, currently trading at $6.93, perilously close to its 52-week low of $6.45. The sharp downturn reflects investor concerns over operational expenses and the impact of weather-related disruptions. According to InvestingPro data, the stock has plummeted 30.81% over the past week and 62% over the last six months. An InvestingPro Tip indicates the RSI suggests the stock is in oversold territory, potentially signaling a buying opportunity for contrarian investors.
For the upcoming quarters, Lumexa projects stable EPS growth, with forecasts of $0.20 for Q3 and $0.24 for Q4 of 2026. Full-year EPS is expected to reach $0.75, with analysts predicting the company will turn profitable this year. The company anticipates revenue growth driven by continued expansion in advanced modalities and strategic service line enhancements. Wall Street analysts see significant upside potential, with price targets ranging from $13 to $23, suggesting potential gains of up to 79% from current levels. For deeper insights into Lumexa’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.
CEO of Lumexa Imaging stated, "Our performance in Q1 2026 underscores our ability to navigate challenges and capitalize on growth opportunities, particularly in advanced modalities." The company emphasized its commitment to expanding its AI-powered solutions and enhancing operational efficiencies.
During the earnings call, analysts inquired about the company’s strategies to mitigate weather-related impacts and manage rising operational costs. Executives highlighted ongoing initiatives to enhance technology integration and expand service offerings, particularly in advanced modalities, to drive future growth.
Investors seeking a complete picture can access 9 additional InvestingPro Tips for LMRI, including detailed Fair Value analysis and Financial Health scores. The platform’s comprehensive metrics and expert insights help investors make informed decisions during periods of market volatility.
Operator: As a reminder, today’s program is being recorded. Now I’d like to introduce your host for today’s program, Sue Dooley from Lumexa Investor Relations. Please go ahead.
Sue Dooley, Investor Relations, Lumexa Imaging: Thank you, and hello, everyone. We appreciate you joining us today. Leading today’s call are our Chief Executive Officer, Caitlin Zulla, and Tony Martin, our Chief Financial Officer. Before we begin, I want to note that we’ll be discussing non-GAAP financial measures we consider helpful in evaluating Lumexa’s performance. You can find details of how these relate to our GAAP measures along with reconciliations in the press release available on our website. We will also be making forward-looking statements based on our current expectations and assumptions, which are subject to risks and uncertainties, including factors listed in our press release and in our various SEC filings. Actual results could differ materially, and we assume no obligation to update these forward-looking statements. With that, I’ll turn the call over to Caitlin. Caitlin, please go ahead.
Caitlin Zulla, Chief Executive Officer, Lumexa Imaging: Thanks, Sue. Thank you all for joining us today. In Q1, we delivered several meaningful achievements to kick off a year executing on our strategic priorities, which include driving strong same-center growth with an expanding mix of advanced modalities, targeting a record number of de novo openings, ensuring the successful ramp of newly opened centers, accelerating high-impact strategic service lines, and expanding our geographic footprint. Here are a few highlights of our announcement tonight. Our Q1 results came in line with our expectations after the seasonal and weather dynamics we discussed in our Q4 call. Q1 volumes ramped throughout March, and we recovered our momentum. Specifically, we drove strong same-center growth and strategic service lines are expanding among a healthy mix of advanced modalities.
In Q1, advanced modalities grew 7% year-over-year, with Positron Emission Tomography growing at 23.1% year-over-year and Magnetic Resonance Imaging growing at 8.2% year-over-year. Rollout of our AI-powered breast arterial calcification solution continues with plans for expansion into new markets and strong continued patient uptake. We are actively ramping de novo centers, and our 2024 and 2025 cohorts are tracking in line with our expectations and advancing our plans towards long-term growth and profit expansion. In some exciting news tonight, we completed two acquisitions and opened two de novos this year, and we are well on our way to achieving our stated goal of opening eight to 10 de novos to fuel future growth.
Meaningfully, one of the acquisitions was an Independent Diagnostic Testing Facility site in Pennsylvania, the first site in our new Joint Venture with University of Pittsburgh Medical Center. We are actively advancing multiple site location plans with this important partner. Finally, we’re excited to welcome two exceptional leaders to Lumexa, each bringing the depth of experience and vision that will help drive our next chapter of growth and results. I’ll go into some more detail in just a moment. At Lumexa, we are addressing a large market opportunity and deploying a disciplined growth algorithm. We are confident we are well-positioned to execute our growth plans while driving better outcomes across the imaging landscape.
I would like to take a moment to speak about our experience in the market as we meet with health systems and the providers who are so important to us and as we continue with our commercial efforts to drive growth and acuity mix. Our value proposition resonates strongly with patients, providers, and payers, reflected in net promoter scores that consistently exceed 90. We deliver high-quality imaging in more convenient settings on a more timely basis and at a meaningfully lower cost than hospital outpatient departments, helping health systems solve important operational challenges and achieve their patient care and market expansion goals.
As we pursue our priorities, it is clear the market is moving towards us. We are benefiting from durable long-term tailwinds, aging populations, new treatment paradigms requiring advanced imaging, rising preventative screening rates, and an ongoing shift from inpatient to outpatient care in a fragmented, capacity-constrained industry.
In our conversations with multiple potential health system partners, they cite struggles with imaging bottlenecks that constrain operational throughput and delay patient access. This underscores a strong need for outpatient capacity and a growing demand for a partner who can deliver speed, access, and capital-efficient expansion. At the same time, many systems are proactively preparing for potential site neutrality by accelerating their shift towards lower-cost outpatient settings, which we believe further reinforces the relevance of our model. They tell us they like our nimble best-of-breed approach that ensures we will always be able to leverage innovation to drive efficiency and the best patient experience and outcomes. As I mentioned a moment ago, reflecting the sizable growth opportunity we are pursuing at Lumexa, we are delighted to welcome two seasoned leaders.
First, Kyle Lynch, our new Chief Growth Officer, brings deep experience in building high-performing business development organizations, executing complex transactions, and implementing growth strategies that translate into durable financial performance. Another proven industry veteran, Rikki Mondo, has joined Lumexa as Chief Enterprise Operations Officer. Rikki has a strong track record of leading and scaling national platforms to drive performance, integration, and operational excellence. As we continue to grow, her focus on enterprise-wide alignment will be critical to delivering for our patients, partners, and teams. Welcome, Kyle and Rikki. We are thrilled to have you join our team to help drive disciplined, efficient, and sustainable growth through joint ventures, de novo development acquisitions, and commercial growth initiatives. Now a moment on the key elements of our growth algorithm. Our commercial team is laser-focused on driving same-center growth.
On the heels of a successful New Jersey launch, we expanded our AI-powered breast arterial calcification program to include New York, and in both markets we are seeing strong acceptance for this cash add-on assessment for cardiac health in women. Our team continued their focus on driving advanced imaging. PET and MRI are strategic areas of focus for us. Additional seasonal campaigns targeted gastroenterologists and Ear, Nose, and Throat specialis